0115-1122 : Galantamine Hydrobromide 24 mg 24 Hr Extended Release Capsule


NDC: 0115-1122
Labeler: Global Pharmaceuticals, Division of Impax Laboratories Inc.
Product Type: Human Prescription Drug
Drug Name:  Galantamine Hydrobromide
Dosage Form: Oral Capsule, Extended Release
Application #: ANDA078484
Rev. Date: 


Appearance:


Markings: E43
Shapes:  Capsule
Colors:  White / White
Size (mm): 19
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 0115-1122-03: 1000 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (0115‑1122‑03)
  • 0115-1122-08: 30 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (0115‑1122‑08)
  • 0115-1122-10: 90 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (0115‑1122‑10)

Active Ingredients:

  • Galantamine Hydrobromide

Dosage Strength:

  • 24 mg

Inactive Ingredients:

  • Hypromellose 2910 (6 Cps)
  • Polyethylene Glycol 400
  • Polyethylene Glycol 8000
  • Raw Sugar
  • Talc
  • Hypromellose 2910 (5 Cps)
  • Ethylcellulose
  • Diethyl Phthalate
  • Gelatin
  • Titanium Dioxide
  • Ferrosoferric Oxide
  • Ferric Oxide Red
  • Ferric Oxide Yellow

Pharmaceutical Classes:

  • Cholinesterase Inhibitor [EPC]
  • Cholinesterase Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 0115-1120 Galantamine Hydrobromide 8 mg 24 Hr Extended Release Capsule by Global Pharmaceuticals, Division of Impax Laboratories Inc.
  • 0115-1121 Galantamine Hydrobromide 16 mg 24 Hr Extended Release Capsule by Global Pharmaceuticals, Division of Impax Laboratories Inc.
  • 0378-8105 Galantamine Hydrobromide 8 mg 24 Hr Extended Release Capsule by Mylan Pharmaceuticals Inc.
  • 0378-8106 Galantamine Hydrobromide 16 mg 24 Hr Extended Release Capsule by Mylan Pharmaceuticals Inc.
  • 0378-8107 Galantamine Hydrobromide 24 mg 24 Hr Extended Release Capsule by Mylan Pharmaceuticals Inc.
  • 0555-1020 Galantamine Hydrobromide 8 mg 24 Hr Extended Release Capsule by Barr Laboratories Inc.
  • 0555-1021 Galantamine Hydrobromide 16 mg 24 Hr Extended Release Capsule by Barr Laboratories Inc.
  • 0555-1022 Galantamine Hydrobromide 24 mg 24 Hr Extended Release Capsule by Barr Laboratories Inc.
  • 0591-3496 Galantamine Hydrobromide 8 mg 24 Hr Extended Release Capsule by Watson Laboratories, Inc.
  • 0591-3497 Galantamine Hydrobromide 16 mg 24 Hr Extended Release Capsule by Watson Laboratories, Inc.
  • 0591-3498 Galantamine Hydrobromide 24 mg 24 Hr Extended Release Capsule by Watson Laboratories, Inc.
  • 10147-0881 Galantamine 4 mg (As Galantamine Hydrobromide 5.126 mg) Oral Tablet by Patriot Pharmaceuticals, LLC
  • 10147-0882 Galantamine 8 mg (As Galantamine Hydrobromide 10.253 mg) Oral Tablet by Patriot Pharmaceuticals, LLC
  • 10147-0883 Galantamine 12 mg (As Galantamine Hydrobromide 15.379 mg) Oral Tablet by Patriot Pharmaceuticals, LLC
  • 10147-0891 Galantamine Hydrobromide 8 mg 24 Hr Extended Release Capsule by Patriot Pharmaceuticals, LLC
  • 10147-0892 Galantamine Hydrobromide 16 mg 24 Hr Extended Release Capsule by Patriot Pharmaceuticals, LLC
  • 10147-0893 Galantamine Hydrobromide 24 mg 24 Hr Extended Release Capsule by Patriot Pharmaceuticals, LLC
  • 43353-984 Galantamine Hydrobromide 16 mg Oral Capsule, Extended Release by Aphena Pharma Solutions - Tennessee, LLC
  • 47335-835 Galantamine Hydrobromide 8 mg 24 Hr Extended Release Capsule by Sun Pharma Global Fze
  • 47335-836 Galantamine Hydrobromide 16 mg 24 Hr Extended Release Capsule by Sun Pharma Global Fze
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0115-1122 QR Code

< Prev: 0115-1121Next: 0115-1150 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.